This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (80)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Surgical Interventions  • Urology  • Prostate Disease  • Oncology  • Prostate Cancer  • Alert me on articles by topic

Nima Sharifi, MD; James L. Gulley, MD, PhD; William L. Dahut, MD

JAMA. 2005;294:238-244.

Context  Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease.

Objective  To review systematically the evidence on the risks and benefits of ADT for prostate cancer as well as clinical management of its adverse effects.

Evidence Acquisition  We performed MEDLINE searches of English-language literature (1966 to March 2005) using the terms androgen deprivation therapy, hormone treatment, and prostate cancer. We reviewed bibliographies of literature to extract other relevant articles. Studies were selected based on clinical pertinence, with an emphasis on controlled study design.

Evidence Synthesis  Androgen deprivation therapy is effective for palliation in many patients with advanced prostate cancer and improves outcomes for high-risk patients treated with radiation therapy for localized disease. Although patients with increasing prostate-specific antigen levels after local treatment without metastatic disease frequently undergo ADT, the benefits of this strategy are not clear. Adverse effects of ADT include decreased libido, impotence, hot flashes, osteopenia with increased fracture risk, metabolic alterations, and changes in cognition and mood.

Conclusions  Androgen deprivation therapy has clear roles in the management of advanced prostate cancer and high-risk localized disease. The benefits of ADT in other settings need to be weighed carefully against substantial risks and adverse effects on quality of life.

Author Affiliations: Medical Oncology Clinical Research Unit (Drs Sharifi, Gulley, and Dahut) and Laboratory of Tumor Immunology and Biology (Dr Gulley), National Cancer Institute, Bethesda, Md; Cytokine Molecular Mechanisms Section, Laboratory of Molecular Immunoregulation, National Cancer Institute, Frederick, Md (Dr Sharifi).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Androgen Deprivation Therapy, Insulin Resistance, and Cardiovascular Mortality: An Inconvenient Truth
Basaria
J Androl 2008;29:534-539.
ABSTRACT | FULL TEXT  

Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical Prostatectomy
Donovan et al.
JCO 2008;26:3923-3929.
ABSTRACT | FULL TEXT  

The Genetics of Castration-Resistant Prostate Cancer: What Can the Germline Tell Us?
Sharifi et al.
Clin. Cancer Res. 2008;14:4691-4693.
ABSTRACT | FULL TEXT  

Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy
Madan et al.
Clin. Cancer Res. 2008;14:4526-4531.
ABSTRACT | FULL TEXT  

Management of Complications of Prostate Cancer Treatment
Michaelson et al.
CA Cancer J Clin 2008;58:196-213.
ABSTRACT | FULL TEXT  

Dietary n-3 Polyunsaturated Fatty Acids Enhance Hormone Ablation Therapy in Androgen-Dependent Prostate Cancer
McEntee et al.
Am. J. Pathol. 2008;173:229-241.
ABSTRACT | FULL TEXT  

Rapid Testosterone Cycling and Chemotherapy for Prostate Cancer: A Way Forward or Return to the Past?
Smith
JCO 2008;26:2932-2933.
FULL TEXT  

Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
Shahani et al.
J. Clin. Endocrinol. Metab. 2008;93:2042-2049.
ABSTRACT | FULL TEXT  

Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer
Hamada et al.
Clin. Cancer Res. 2008;14:3312-3318.
ABSTRACT | FULL TEXT  

Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study
Smith et al.
JCO 2008;26:1824-1829.
ABSTRACT | FULL TEXT  

Transforming growth factor-{beta} receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?
Sharifi et al.
J Mol Endocrinol 2007;39:329-332.
ABSTRACT | FULL TEXT  

The role of Src in prostate cancer
Fizazi
Ann Oncol 2007;18:1765-1773.
ABSTRACT | FULL TEXT  

p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells
Roy et al.
Molecular Cancer Therapeutics 2007;6:2696-2707.
ABSTRACT | FULL TEXT  

A bifunctional colchicinoid that binds to the androgen receptor
Sharifi et al.
Molecular Cancer Therapeutics 2007;6:2328-2336.
ABSTRACT | FULL TEXT  

Retinoblastoma Tumor Suppressor Status Is a Critical Determinant of Therapeutic Response in Prostate Cancer Cells
Sharma et al.
Cancer Res. 2007;67:6192-6203.
ABSTRACT | FULL TEXT  

Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Bruxvoort et al.
Cancer Res. 2007;67:2490-2496.
ABSTRACT | FULL TEXT  

Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer
Wu and Huang
J. Biol. Chem. 2007;282:3571-3583.
ABSTRACT | FULL TEXT  

Radiotherapy for Prostate Cancer
Rutz et al.
NEJM 2007;356:308-311.
FULL TEXT  

Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning R3327-H Prostate Adenocarcinomas
Canene-Adams et al.
Cancer Res. 2007;67:836-843.
ABSTRACT | FULL TEXT  

Obesity and Sex Steroids during Gonadotropin-Releasing Hormone Agonist Treatment for Prostate Cancer
Smith
Clin. Cancer Res. 2007;13:241-245.
ABSTRACT | FULL TEXT  

Prostate Cancer in a Transgender Woman 41 Years After Initiation of Feminization.
Miksad et al.
JAMA 2006;296:2316-2317.
FULL TEXT  

Treatment-related osteoporosis in men with prostate cancer.
Smith
Clin. Cancer Res. 2006;12:6315s-6319s.
ABSTRACT | FULL TEXT  

Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
Keating et al.
JCO 2006;24:4448-4456.
ABSTRACT | FULL TEXT  

Gene therapy for cancer treatment: past, present and future.
Cross and Burmester
Clin Med Res 2006;4:218-227.
ABSTRACT | FULL TEXT  

Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
Kim et al.
JNCI J Natl Cancer Inst 2006;98:783-793.
ABSTRACT | FULL TEXT  

Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer
Smith et al.
J. Clin. Endocrinol. Metab. 2006;91:1305-1308.
ABSTRACT | FULL TEXT  

Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Greenspan et al.
J. Clin. Endocrinol. Metab. 2005;90:6410-6417.
ABSTRACT | FULL TEXT